AMD Sinks 10.5% as Chip Rally Unwinds, Nasdaq 100 Falls 1.7%: Stock Market Today
AMD lost about $100 billion as traders unwound the post-Huang chip rotation, Nvidia's China scandal deepened and Cisco slid on margins. QQQ fell 1.7%.
Viking Therapeutics, Inc. (VKTX)
NASDAQ
$29.22
+$1.65
(+5.98%)
Previous Close: $27.58
Market Closed
Viking Therapeutics, Inc. (VKTX) Live Price Chart
Last updated: 2026-11-14 19:41:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Viking Therapeutics, Inc. (VKTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $29.22, with a market capitalization of $3.52B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.82 to $43.10. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$3.52B | |
$27.44 | |
$29.88 | |
$26.69 | |
$27.58 | |
8.39M | |
5.23M | |
-- | |
$43.10 | |
$23.82 | |
-- | |
12-31 |
Viking Therapeutics, Inc. (VKTX) Latest Closing Stock Price
Viking Therapeutics, Inc. (VKTX) last closed at $29.22 as of 2026-11-14 01:00:00, up 5.98% ($1.65) from the previous close of $27.58.
During the latest regular trading session, VKTX traded between $26.69 and $29.88, with a volume of 8.39M shares. The closing price was near the upper end and near the lower end of its 52-week range.
Viking Therapeutics, Inc. (VKTX) 7-Day Stock Price Change
Over the past seven days, Viking Therapeutics, Inc. (VKTX) moved from $25.79 to $29.22, representing a gain of 13.30% ($3.43).
The stock traded between $25.37 and $30.10 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 4.23 million shares, down versus the previous seven-day period, indicating lower trading activity.
VKTX 52-Week Price Position
Position in Range: 28.0%
52W Low$23.82
52W High$43.10
VKTX is currently trading at $29.22, placing it 28.0% of the way from its 52-week low of $23.82 to its 52-week high of $43.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Viking Therapeutics, Inc. (VKTX)?
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Viking Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 74 |
| CEO | Brian Lian |
| Founded | 2012 |
| Exchange | NASDAQ |
| Company Website |
VKTX News
Latest news related to Viking Therapeutics, Inc. and VKTX stock.
- BenzingaRead Full Article
- MassiveRead Full Article
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Viking Therapeutics is conducting phase 3 trials for its obesity drug VK2735 in both injectable and oral forms. The oral formulation could expand the addressable market through a dual-dosing strategy. With conservative assumptions of 50% phase 3 success rate and 10% market share of tirzepatide's peak sales, Viking's stock could reach $110 per share by 2028, making a $10,000 investment worth up to $47,800.
- MassiveRead Full Article
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
Eli Lilly raised its 2026 sales forecast to $91-92 billion, driven by strong Zepbound weight-loss drug sales. While smaller competitor Viking Therapeutics shows promise with its VK2735 candidate demonstrating encouraging clinical trial results, Eli Lilly's diversified pipeline and market leadership position it well to withstand competition. Viking offers high upside potential but carries significant clinical and regulatory risks.
- MassiveRead Full Article
GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
- MassiveRead Full Article
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
Novo's newly launched Wegovy oral pill generated DKK 5.4 billion in Q3 2026 sales with 3.6 million U.S. prescriptions, prompting the company to raise its 2026 growth outlook. However, the company faces intense competition from Eli Lilly's surging Mounjaro and Zepbound sales, as well as emerging competitors like Viking Therapeutics and Structure Therapeutics developing alternative GLP-1 therapies. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation.
Ways to Trade VKTX at MEXC
How to Buy Viking Therapeutics, Inc. (VKTX) Stock on MEXC
Eligible investors can buy real shares of Viking Therapeutics, Inc. (VKTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for VKTX and Place Your Order
Open the RealStocks trading page and search for VKTX. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.
Frequently Asked Questions (FAQ)
1.What is Viking Therapeutics, Inc. (VKTX) stock price today?
Viking Therapeutics, Inc. (VKTX) is currently trading at $29.22, up 5.98% ($1.65) from the previous close of $27.58. Intraday prices update in real time during regular trading hours.
2.Is VKTX stock going up or down today?
As of 2026-11-14 01:00:00, VKTX is trading at $29.22, up 5.98% ($1.65) from its previous close of $27.58. The stock has traded between $26.69 and $29.88 during today’s regular session. Past price movements do not guarantee future results.
3.What is VKTX pre-market price?
As of 2026-11-14 01:00:00, VKTX is trading at $27.75 in pre-market trading, up 0.62% ($0.17) from the previous close of $27.58. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is VKTX after-hours price?
As of 2026-11-14 01:00:00, VKTX is trading at $29.14 in after-hours trading, down 0.29% ($0.09) from the regular-session close of $29.22. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is VKTX stock trading now?
VKTX trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does VKTX sit relative to its 52-week high and low?
Over the past 52 weeks, VKTX has traded between a low of $23.82 and a high of $43.10. At $29.22, the stock is positioned 28.0% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Viking Therapeutics, Inc. in?
Viking Therapeutics, Inc. (VKTX) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Viking Therapeutics, Inc.'s market capitalization and where is it listed?
Viking Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of $3.52B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is VKTX valued in terms of P/E ratio and EPS?
VKTX trades at a P/E ratio of --, based on trailing-twelve-month EPS of $-4.92. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Viking Therapeutics, Inc. pay a dividend?
Viking Therapeutics, Inc. pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.
Explore More US Stocks
Stocks in the Same Sector
Browse other US stocks in the same sector as Viking Therapeutics, Inc.
Largest Market Cap
See US stocks with the highest market capitalization
Most Actively Traded
Discover today's most actively traded US stocks
Top Gainers
Browse today's leading gainers in the US stock market
Top 5 Cryptocurrencies
Explore the cryptocurrencies with the highest market capitalization
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to VKTX, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
VKTX Stock Calculator
Estimate the value between VKTX shares and USD.
VKTX Shares to USD
VKTX Shares
VKTX
USD
USD
1.00 VKTX shares = 29.221 USD
Calculations are estimates based on the latest available price and are for reference only.